Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), to explore innovative applications of AI in cancer research. This collaboration aims to advance research into the tumor microenvironment and immune phenotyping, analyzing NCI data to uncover insights that could drive personalized cancer care.

Under the agreement, Lunit tools will be made available to NCI Center for Cancer Research (CCR) investigators, across NCI CCR's portfolio of clinical trials. Lunit will analyze whole-slide images obtained from NCI's clinical studies, using Lunit AI-powered biomarker technologies, including Lunit SCOPE^® IO and Lunit SCOPE universal IHC. This broad collaboration will enable image-analysis AI to become a core part of cancer research practice.

The two parties plan to jointly prepare publications, presentations, and reports. The primary objective of this partnership is to develop data-driven insights that can help personalize treatment approaches for cancer patients. By applying Lunit's AI solutions across NCI's extensive cancer research portfolio, the collaboration seeks to accelerate discoveries that optimize immunotherapy strategies, improve patient outcomes, and pave the way for more targeted cancer care.

"This collaboration with the NCI is a testament to the power and potential of Lunit's AI-driven solutions in advancing the frontier of cancer research," said Brandon Suh, CEO of Lunit. "By applying our technologies across NCI's unparalleled research expertise and clinical data, we aim to uncover meaningful insights that can transform cancer treatment and deliver more personalized care to patients worldwide. We are honored to work with one of the world's leading cancer research institutions to tackle some of the toughest challenges in oncology."